TY - JOUR
T1 - Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma
T2 - a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)
AU - Lombardi, Giuseppe
AU - Pace, Andrea
AU - Pasqualetti, Francesco
AU - Rizzato, Simona
AU - Faedi, Marina
AU - Anghileri, Elena
AU - Nicolotto, Elisa
AU - Bazzoli, Elena
AU - Bellu, Luisa
AU - Villani, Veronica
AU - Fabi, Alessandra
AU - Ferrazza, Patrizia
AU - Gurrieri, Lorena
AU - Dall’Agata, Monia
AU - Eoli, Marica
AU - Della Puppa, Alessandro
AU - Pambuku, Ardi
AU - D’Avella, Domenico
AU - Berti, Franco
AU - Rudà, Roberta
AU - Zagonel, Vittorina
PY - 2015/11/1
Y1 - 2015/11/1
N2 - The efficacy of temozolomide (TMZ) plus radiation therapy (RT) in elderly patients with glioblastoma is unclear. We performed a large multicenter retrospective study to analyze prognostic factors and clinical outcome in these patients. Inclusion criteria were age ≥65 years, newly histologically confirmed glioblastoma, ECOG PS 0-2, adjuvant treatment with RT plus TMZ. We enrolled 237 patients; the average age was 71 and ECOG PS was 0-1 in 196 patients; gross total resection was performed in 174 cases. MGMT was analyzed in 151 persons and was methylated in 56 %. IDH1 was assessed in 100 patients and was mutated in 6 %. Seventy-one patients were treated with RT 40 Gy and 166 with RT 60 Gy. Progression-free survival and overall survival (OS) were 11.3 and 17.3 months, respectively. Overall survival was 19.4 vs 13.8 months for patients treated with RT 60 Gy and 40 Gy (p = 0.02); OS was 17.7 versus 16.1 months for patients treated with gross total resection vs partial surgery (p = 0.02); OS was 21.2 versus 13.6 months for methylated and unmethylated MGMT (p
AB - The efficacy of temozolomide (TMZ) plus radiation therapy (RT) in elderly patients with glioblastoma is unclear. We performed a large multicenter retrospective study to analyze prognostic factors and clinical outcome in these patients. Inclusion criteria were age ≥65 years, newly histologically confirmed glioblastoma, ECOG PS 0-2, adjuvant treatment with RT plus TMZ. We enrolled 237 patients; the average age was 71 and ECOG PS was 0-1 in 196 patients; gross total resection was performed in 174 cases. MGMT was analyzed in 151 persons and was methylated in 56 %. IDH1 was assessed in 100 patients and was mutated in 6 %. Seventy-one patients were treated with RT 40 Gy and 166 with RT 60 Gy. Progression-free survival and overall survival (OS) were 11.3 and 17.3 months, respectively. Overall survival was 19.4 vs 13.8 months for patients treated with RT 60 Gy and 40 Gy (p = 0.02); OS was 17.7 versus 16.1 months for patients treated with gross total resection vs partial surgery (p = 0.02); OS was 21.2 versus 13.6 months for methylated and unmethylated MGMT (p
KW - Chemotherapy
KW - Elderly
KW - Glioblastoma
KW - Radiation therapy
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=84945196449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945196449&partnerID=8YFLogxK
U2 - 10.1007/s11060-015-1923-x
DO - 10.1007/s11060-015-1923-x
M3 - Article
C2 - 26423801
AN - SCOPUS:84945196449
VL - 125
SP - 359
EP - 367
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 2
ER -